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Concise report
Disease activity dynamics in rheumatoid arthritis:
patients’ self-assessment of disease activity via
WebApp
Ulrich A. Walker1,*, Ruediger B. Mueller2,*, Veronika K. Jaeger1, Robert Theiler3,
Adrian Forster4, Patrick Dufner5, Fabiana Ganz5 and Diego Kyburz1
Abstract
Objectives. The aim was to evaluate patient self-assessment of RA disease activity in terms of Routine
Assessment of Patient Index Data (RAPID) scores via a Web-based smartphone application (WebApp).
Methods. In this prospective, multicentre study, adult RA patients were examined by a rheumatologist at
baseline and after 3 months. Patients were asked to complete WebApp questionnaires weekly. The time
course of patient-assessed RAPID3/4 scores and their correlations with rheumatologist-assessed DAS28,
as well as Clinical and Simplified Disease Activity Indices (CDAI/SDAI), were evaluated.
Results. Eighty patients were included in the analysis (median RA duration, 4.5years; age, 57 years; 59%
female). At baseline, there was a moderate to strong correlation between RAPID3 and DAS28 (r= 0.63), CDAI
(r= 0.65) and SDAI (r= 0.61) scores. Similar or stronger correlations were seen at the 3-month follow-up visit
(DAS28 r= 0.66, CDAI r= 0.71 and SDAI r= 0.61). Similar correlations were seen between RAPID4 and
rheumatologist assessments. Correlations were not influenced by demographics or RA treatment. In the 3-
month period, the RAPID3 score changed into a higher severity category than the category at baseline at
least once in 47% of patients. When DAS28 scores were predicted from the RAPID3, 11% of patients had an
increase of> 1 DAS28 unit during the 3-month observation period.
Conclusion. Web-based patient assessments were strongly correlated with rheumatologist assessments
of RA activity and showed considerable variation during follow-up. This provides a rationale for further
exploration of their use as cost-effective tools to monitor RA activity between outpatient visits and to
optimize tight control strategies.
Key words: rheumatoid arthritis, patient’s self-assessment, patient-reported outcome, tight control, RAPID
score
Rheumatology key messages
. Patients can reliably self-assess their RA activity by means of a WebApp.
. Patients’ assessed RA activity fluctuates considerably in between rheumatologist visits.
Introduction
Current RA treatment guidelines recommend the use of
clinical measures, for instance, the DAS based on 28
joints (DAS28), in the assessment of disease activity and
treatment success to achieve tight disease control [1].
Tight disease control implies that physicians must
enable timely adaptation of therapy, which requires inten-
sive disease activity monitoring [2]. In clinical practice,
however, patients with RA are usually seen by
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rheumatologists only every 36 months as, although de-
sirable, more frequent visits are often not possible be-
cause of limited resources.
Patient involvement in disease management and a
shared decision-making approach is not only recom-
mended by the EULAR, but also preferred by most RA
patients [35]. Innovative solutions are thus needed from
the physicians’ and from the patients’ perspective to
monitor disease activity in between clinic visits to improve
clinical management of patients with RA.
Patient-reported outcomes (PROs) are increasingly recog-
nized for their value in providing the patient’s perspective on
their health and quality-of-life status and are hence essential
in the judicious care of RA patients [6, 7]; the use of PROs in
clinical practice is also recommended by EULAR to comple-
ment disease monitoring [4, 5]. With limited resources of
health-care professionals and an increasing focus on pa-
tient-centred care, continuous monitoring of RA disease ac-
tivity might be achievable because of regular patients’ self-
assessment of disease activity using valid and reliable PROs.
With the development of new technology, PRO question-
naires are becoming available as Web-based applications
(WebApps) for computers and smartphones [8].
The Routine Assessment of Patient Index Data 3 and 4
(RAPID3/RAPID4) are PRO tools for RA self-assessment
by the patient [9]. The RAPID3 is one of the most exten-
sively validated PRO tools, with strong internal consist-
ency and structural validity, and is recommended by the
ACR as a disease activity measure for use in clinical prac-
tice because of its sensitivity to change and ability to dis-
criminate well between disease activity states [10, 11].
Additionally, the RAPID3 takes only 1.5 min to complete
[12]. Several studies have demonstrated good correl-
ations between paper-based RAPID-based assessments
and clinical measures of RA activity, such as the DAS28
and the Clinical Disease Activity Index (CDAI) [9, 13].
Additionally, RAPID-based assessments have been
shown to be cost effective and time efficient in a home-
based monitoring or busy clinical setting [9, 13].
The COmPASS study aimed to evaluate the COrrelation
between PAtient self-ASSessment of RA activity using
RAPID scores via WebApp and physician RA activity as-
sessments using traditional scores. Additionally, this
study aimed to evaluate RA activity dynamics between
routine clinical visits using RAPID scores.
Methods
Study population and design
This prospective, multicentre study was conducted between
November 2012 and March 2014 across five sites in
Switzerland after approval from the centres’ independent
ethics committees. Adult RA patients were eligible if
they received or began treatment with conventional or s.c.
DMARDs or both, according to the Swiss label (see Inclusion
and exclusion criteria section of supplementary data, avail-
able at Rheumatology Online). This study was approved by
the following ethical committees: Ethikkommission Nordwest
und Zentralschweiz, Kantonale Ethikkommission Bern,
Ethikkommission des Kantons St Gallen, Ethikkommission
Thurgau and Kantonale Ethikkommission Zu¨rich. Each pa-
tient provided written informed consent.
Patients were equipped with smartphones (iPhone 3),
were educated how to use the WebApp, and had the
chance to familiarize themselves with the application for
2 weeks before the baseline visit. At baseline and the 3-
month follow-up visit, the RA activity of patients was as-
sessed by a rheumatologist. At baseline and during the
subsequent 3 months, patients were asked to provide
weekly self-assessments on the WebApp.
Study measures and outcomes
The following measures were collected by the rheuma-
tologists: DAS28 (based on CRP [14]), the CDAI and
the Simplified Disease Activity Index [15]. For more
information, see the Collected outcome measures sec-
tion of supplementary data, available at Rheumatology
Online.
Information captured with the WebApp included the
RAPID3 and RAPID4 (range 030 and 040, respectively,
with higher scores indicating more active disease), the
latter of which also includes the patient’s self-reported
joint count [9].
After 3 months, the user friendliness and usability of the
WebApp was evaluated by patients using the System
Usability Scale (range 0100; see System usability scale
section of supplementary data, available at Rheumatology
Online) [16]. The value of the WebApp for patientphys-
ician communication was assessed by patients and phys-
icians using a 100-mm visual analog scale (see
Patientphysician communication section of supplemen-
tary data, available at Rheumatology Online).
Statistical analysis
Baseline and follow-up scores were compared using
WilcoxonMannWhitney tests. Correlations between the
outcome measures were analysed using the Spearman’s
correlation coefficient. Multiple linear regression analyses
were carried out to assess the potentially confounding
effect of variables defined a priori.
The absolute dynamics of the RAPID3 score was calcu-
lated as the sum of RAPID3 fluctuations (differences from
the baseline RAPID3 score) divided by the number of
RAPID3 entries. Likewise, the percentage of the average
fluctuation in RAPID3 score was calculated. The DAS28
and CDAI scores between clinical visits were predicted
from the RAPID3 scores based on a linear regression
model. The number of patients who had an increase in
the predicted DAS28 and CDAI of more than the minimally
clinically important difference (MCID) at any time was as-
sessed [17]. All data were analysed using Stata 13.1
(StataCorp, College Station, TX, USA).
Results
Patient and disease characteristics
Five Swiss centres screened 92 patients, of whom 80
patients were included in this analysis (supplementary
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Fig. S1, available at Rheumatology Online). Demographic,
socio-economic and baseline disease activity character-
istics are provided in Table 1. There were no significant
differences between baseline and follow-up scores with
regard to all clinical or patient self-assessed disease ac-
tivity measures (all P> 0.15).
Correlations between RAPID3/4 and clinical scores
The correlation between the RAPID3 and DAS28 was
strong at baseline and at the 3-month follow-up (r= 0.63
and r= 0.66, respectively; Table 2). The same was true for
the correlations between RAPID3 and the other physician
assessments of RA activity (Table 2).
Notably, the correlation between the RAPID4 and
DAS28 was similar to that of RAPID3 and DAS28, both
at baseline (r= 0.63 vs 0.64) and at the 3-month follow-
up visit (r= 0.66 vs 0.67; Table 2). The same was true for
the correlations between the RAPID4 and the other phys-
ician-reported assessments (Table 2).
At baseline, the relationship between the clinical scores
and the RAPID3/4 scores was not confounded by sex,
age, native language, current DMARD use or prior smart-
phone experience (supplementary Table S1, available at
Rheumatology Online).
RA activity at baseline and follow-up
On average, there were 90 days (S.D. 11) between the
baseline and the follow-up visits; the average interval be-
tween WebApp entries was 10 days (S.D. 5.3).
When comparing DAS28 activity strata at baseline and
after 3 months (Table 1), the RA activity did not change as
measured by DAS28 activity strata in 59% of individuals.
At the follow-up visit, 16% of patients were in a higher
DAS28 activity category than at baseline, whereas 25%
of patients were categorized into a lower DAS28 activity
category.
RA activity dynamics: RAPID3
During the 3-month observation period, the RAPID3 se-
verity category was higher than the baseline RAPID3 cat-
egory at least once in 47% of the patients. Of these
patients, 61% changed into a higher category once,
25% twice, 11% three times and 3% four times (supple-
mentary Table S2, available at Rheumatology Online). In
between these changes, the patients either remained in
the same RAPID3 category or fell into a lower severity
category. Among the patients who were in DAS28 remis-
sion at baseline, 53% changed into a higher RAPID3 cat-
egory at least once during the follow-up compared with
33% of patients with low RA disease activity and 35% of
patients with moderate RA activity.
Details on the variation of the RAPID3 scores over the
study period are provided in supplementary Fig. S2, avail-
able at Rheumatology Online. The greatest absolute fluc-
tuations of the RAPID3 score were observed in those
patients who were already in the high RAPID3 category
at baseline (supplementary Fig. S2D, available at
Rheumatology Online). In these patients, the median
RAPID3 fluctuation from the baseline RAPID3 score was
3.7 units [interquartile range (IQR): 1.95.5], compared
with 2.3 units (IQR: 1.74.1) in patients with moderate
RAPID3 disease severity, 2.0 units (IQR: 1.43.4) in pa-
tients with low RAPID3 disease severity and 0.9 units
(IQR: 0.41.4) in patients in RAPID3 remission.
RA activity dynamics: predicted DAS28
For further analysis of the relevance of observed changes
in RAPID3 scores during the 3-month observation period,
we predicted the DAS28 scores in between the baseline
and follow-up visits based on the RAPID3 during the ob-
servation period. Using this prediction, 11.3% of patients
would have increased by >1 DAS28 unit during the ob-
servation period, which is regarded the DAS28 MCID [17].
This increase was first observed at a median of 47 days
(IQR: 2181) after baseline. The highest percentage of pa-
tients with an increase in the predicted DAS28 higher than
the MCID was observed in patients with a low DAS28
disease activity at baseline (16.7%) compared with
11.6% in patients in remission, 10.0% in patients with
moderate disease activity and 0% in patients with high
disease activity at baseline. For results on the predicted
CDAI, see RA activity dynamics over time—predicted
CDAI section of supplementary data, available at
Rheumatology Online.
WebApp evaluation
The System Usability Scale indicated a median score of
85 (IQR: 7393) at the follow-up visit, suggesting that pa-
tients rated the WebApp as very positive in terms of ease
of use; a score of 68 is considered average [16]. Patients
and physicians rated the benefit of the WebApp on the
patientphysician communication with a median score of
74 (IQR: 4393) and 50 (IQR 1860), respectively, on the
100-mm visual analog scale.
Discussion
In this study, patient self-assessment of RA disease ac-
tivity via smartphone technology was demonstrated to be
correlated strongly with clinical outcome parameters re-
corded by physicians. Although RAPID scores have al-
ready been shown to be correlated reproducibly with
clinical outcomes in clinical practice and research [9,
13], our study now extends the data derived from paper-
based data recordings to the use of WebApps. This offers
benefits in terms of automated scoring, continuous data
capture outside the physician’s office and partial outsour-
cing of RA monitoring to the patient, saving time for the
healthcare professional. This WebApp-based approach
has demonstrated feasibility, as there was a high degree
of engagement with the technology in terms of regular
data entry by patients. Furthermore, patients assessed
the tool as easy to use and saw value in the WebApp as
a positive support tool to physicianpatient communica-
tion. Owing to the ease of use and intuitive nature of the
WebApp, elderly patients and patients with no prior smart-
phone experience were also able to use the WebApp;
www.rheumatology.oxfordjournals.org 1709
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TABLE 1 Demographic, socio-economic and clinical characteristics of the study population at baseline and the follow-
up visit
Characteristic (n =80) Baseline 3-month follow-up
Female, % 58.8
Age, median (IQR), years 57.3 (44.965.9)
Education
Compulsory schooling not completed, % 5.0
Compulsory schooling completed, % 48.8
Secondary school level, % 20.0
University or similar, % 26.3
Prior smartphone use, % 50.0
Native language
German, % 85.0
Other, % 15.0
Currently employed, % 43.6
RA duration since diagnosis, median (IQR), years 4.5 (1.19.5)
RA symptom duration, median (IQR), years 5.1 (1.612.2)
DMARD use, % 82.5 92.5
Biologic DMARD use, % 31.3 39.2
DAS28
Median (IQR) 2.4 (1.93.5) 2.4 (1.73.7)
42.6 (remission), % 55.8 54.8
>2.6 to4 3.2 (low disease activity), % 15.6 12.3
>3.2 to4 5.1 (moderate disease activity), % 26.0 26.0
>5.1 (high disease activity), % 2.6 6.9
CDAI
Median (IQR) 7.6 (4.316.5) 5.7 (2.014.2)
42.8 (remission), % 16.9 33.3
>2.8 to4 10 (low disease activity), % 44.1 35.9
>10 to4 22 (moderate disease activity), % 27.3 15.4
>22 (high disease activity), % 11.7 15.4
SDAI
Median (IQR) 10.5 (6.620.4) 8.6 (4.922.1)
43.3 (remission), % 10.7 11.0
>3.3 to4 11 (low disease activity), % 44.0 47.9
>11 to4 26 (moderate disease activity), % 28.0 23.3
>26 (high disease activity), % 17.3 17.8
RAPID3
Median (IQR) 6.6 (3.111.9) 6.4 (2.612.3)
43 (near remission), % 25.0 28.7
3.1 to4 6 (low severity), % 21.2 18.8
6.1 to4 12 (moderate severity), % 28.8 27.5
>12.1 (high severity), % 25.0 25.0
RAPID4
Median (IQR) 7.8 (3.515.1) 7.6 (3.015.8)
44 (near remission), % 30.0 32.5
4 to4 8 (low severity), % 20.0 18.8
8 to4 16 (moderate severity), % 30.0 23.8
>16 (high severity), % 20.0 25.0
SF-36 PCS, median (IQR) 43.8 (36.552.6) 46.1 (38.653.2)
SF-36 MCS, median (IQR) 50.7 (37.458.0) 50.1 (35.658.9)
HAQ-DI, median (IQR) 0.38 (0.131.13) 0.38 (0.131.25)
FACIT-F, median (IQR) 38 (1547) 38 (2642)
CDAI: Clinical Disease Activity Index; Education: compulsory schooling is defined as 9 years of schooling, and secondary
school level includes vocational training; FACIT-F: Functional Assessment of Chronic Illness Therapy—Fatigue; HAQ-DI: HAQ
Disability Index; IQR: interquartile range; RAPID: Routine Assessment of Patient Index Data; SDAI: Simplified Disease Activity
Index; SF-36 MCS: Short Form-36 Mental Component Summary; SF-36 PCS: Short Form-36 Physical Component Summary.
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hence, this WebApp-based approach seems applicable to
a wide range of patients.
One of the biggest challenges in the management of RA
is monitoring disease effectively, in order to avoid missing
flare-ups. EULAR guidelines suggest that disease activity
should be monitored every 13 months in active RA, be-
cause tight control is more effective in controlling disease
and preventing radiographic progression [4]. During the 3-
month period of this study, 1 in 10 patients reported an
increase in RAPID3 scores that would translate into >1
DAS28 unit, which is regarded as the MCID. These data
suggest that clinically relevant flares may be missed when
physicians are seeing patients at a 3-month interval, even
in supposedly well-controlled patients with low disease
activity or in remission. The population of patients
deemed to have quiescent RA could potentially benefit
from the WebApp by enabling treatment adjustment.
The median time to flare was as short as 47 days, sug-
gesting that WebApp-based disease monitoring could be
used to enable earlier interventions if RAPID flares trig-
gered a timely rheumatologist visit. It is, however, unclear
at present whether an earlier response to patient-reported
flares would indeed offer better control of RA activity; fur-
ther research is needed to quantify this.
Although our exploratory study has limited statistical
power, implying that negative results with respect to po-
tentially confounding factors must be interpreted cau-
tiously, the results of this study support the feasibility of
the continuous patient self-monitoring of RA activity using
a WebApp-based approach in order to capture disease
flares, even in patients deemed quiescent. WebApp-
based RAPID3 data capture may evolve into a means to
collect detailed information about the fluctuations of RA
activity in between outpatient visits and may in the future
optimize RA management.
To further research about continuous self-monitoring,
the randomized COmPASS-II study was initiated in order
to evaluate the effect of patients’ continuous disease ac-
tivity self-assessment by WebApp on RA outcome in a
routine clinical setting [18].
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